Media coverage, page-3

Great write up....

Well, the analysts at Morgan Stanley think ANP is a takeover target for Sarepta - no shit!

With 3 successful Phase 2 results for ATL1102/3, and piddly market cap...the sharks are circling!
—————————————

From the article:

Among the companies Mr Power expects will release clinical trial results or announce news of regulatory approvals before the end of 2019 are Antisense Therapeutics, Volpara Health Technologies, ResApp and Novita Healthcare.

Despite trading at just 10¢ and having a market capitalisation of only $42 million, Antisense already has big institutional investors such as Australian Ethical and Platinum Asset Management on its register, as well as biotech doyen Leon Serry.

The company was established by Circadian Technologies (now Opthea) in 2000 and spun out and listed in late 2001. It is developing two drugs, ATL1102 and ATL1103. The latter has already completed a phase two trial for a disease called acromegaly, while a phase two trial in patients with relapsing-remitting multiple sclerosis has also been completed for ATL1102.

By the year-end, the company is expected to release results of another phase two trial for the use of ATL1102 to treat a rare genetic disorder called Duchenne Muscular Dystrophy. The life expectancy of those suffering from this is only the mid-20s.

If the trial results are positive, Mr Power believes the business will become a takeover target for US pharmaceutical company Sarepta Therapeutics, which manufactures the world's first drug to treat the disease.

"It's treating a disease with very little products out there. Sarepta's product is only effective in 13 per cent of patients and for everyone else, there's virtually no treatments," he said.

"Its share register is very strong, looking at its board they're highly experienced internationally ... and its path to market is pretty clear assuming the clinical results are positive."